Chromogranin peptides in brain diseases.

Area of Science:

• Neuroscience
• Pathophysiology
• Immunohistology

Background:

• Synaptic disturbances are central to neuropsychiatric disease pathophysiology.
• Chromogranin peptides are key components of dense-core vesicles involved in neurotransmission.
• Neuroinflammation is increasingly recognized as a factor in neurodegenerative diseases.

Purpose of the Study:

• To review immunohistological findings of chromogranin peptides in neurodegenerative and neurodevelopmental disorders.
• To focus on the role of chromogranin peptides, particularly chromogranin A, in Alzheimer's disease, schizophrenia, and amyotrophic lateral sclerosis (ALS).
• To explore the link between chromogranin peptides, synaptic function, and neuroinflammation.

Main Methods:

• Review of existing experimental data.
• Analysis of new experimental data.
• Medline research synthesis.

Main Results:

• Chromogranin peptides show altered immunoreactivity in Alzheimer's disease, schizophrenia, and ALS.
• Imbalanced chromogranin peptide availability may impair neurotransmission and dense-core vesicle function.
• Chromogranin A is highlighted for its potential role as a proinflammatory agent in Alzheimer's disease and ALS.

Conclusions:

• Chromogranin peptides are significantly involved in the pathophysiology of studied neuropsychiatric disorders.
• Further research is necessary to fully elucidate the function and role of chromogranin peptides in neuropathological conditions.
• Targeting chromogranin peptides may offer future therapeutic strategies for neurodegenerative and neuropsychiatric diseases.